Melanoma & Skin Cancer

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the activity of the combination of dabrafenib and trametinib alone as well as in combination with spartalizumab in patients with advanced BRAF V600E-mutant melanoma.

The FDA has accepted 6 supplemental biologics license applications for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.

Nikhil Khushalani, MD, discusses the CA045-001 study, a phase III, randomized study that compared bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

Ryan J. Sullivan, MD, discusses the results of the COMBI-d and COMBI-v studies that led to changes in practice for patients with BRAF V600-mutant unresectable or metastatic melanoma.

David Polsky, MD, PhD, discusses using circulating tumor DNA kinetics as a biomarker to predict survival and monitor disease activity in patients with unresectable or metastatic melanoma.

The European Commission approved cemiplimab (Libtayo) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

Ryan J. Sullivan, MD, discusses the success with dabrafenib (Tafinlar) plus trametinib (Mekinist) and highlights the potential added benefit of spartalizumab in BRAF-mutant with melanoma.